European Commission okays state aid for pharma companies
This article was originally published in Scrip
In good news for pharmaceutical companies hit by government austerity measures, the European Commission has okayed a German scheme that exempts struggling companies from the mandatory rebates and price freezes intended to cut costs. Firms should welcome the decision because it means EU countries can use state aid to balance controlling public spending with helping pharma companies survive in difficult conditions, says Johan Ysewyn, a partner at the law firm Covington & Burling.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.